{"id":68851,"date":"2026-06-25T00:08:09","date_gmt":"2026-06-24T16:08:09","guid":{"rendered":"https:\/\/flcube.com\/?p=68851"},"modified":"2026-06-25T00:08:10","modified_gmt":"2026-06-24T16:08:10","slug":"gileads-trodelvy-sacituzumab-govitecan-secures-european-commission-approval-for-first-line-metastatic-tnbc-expanding-adc-access-to-treatment-naive-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68851","title":{"rendered":"Gilead&#8217;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gilead Sciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted marketing authorization for <strong>Trodelvy (sacituzumab govitecan)<\/strong> as a <strong>monotherapy<\/strong> for adult patients with <strong>unresectable or metastatic triple-negative breast cancer (TNBC)<\/strong> who have not received prior systemic therapy for metastatic disease and are <strong>not candidates for PD-1 or PD-L1 inhibitor therapy<\/strong>. This approval significantly expands Trodelvy&#8217;s European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Trodelvy (sacituzumab govitecan) \u2013 Trop-2-directed ADC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line unresectable\/metastatic TNBC in PD-1\/PD-L1 inhibitor-ineligible patients<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>25 Jun 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved in EU; supplemental applications pending with US FDA based on ASCENT-03\/04 studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> <strong>Trop-2-directed antibody-drug conjugate (ADC)<\/strong> targeting a cell-surface antigen expressed in over 90% of breast and lung cancers<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Proprietary <strong>hydrolyzable linker<\/strong> attached to <strong>SN-38 payload<\/strong> (topoisomerase I inhibitor) enabling controlled drug release<\/li>\n\n\n\n<li><strong>Bystander Effect:<\/strong> Unique mechanism delivers potent cytotoxic activity not only to Trop-2-expressing tumor cells but also to neighboring cells in the tumor microenvironment<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses the significant unmet need in first-line metastatic TNBC for patients ineligible for immunotherapy due to contraindications or biomarker status<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-pathway\" class=\"wp-block-heading\">Clinical Development Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Population<\/th><th>Status<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>ASCENT-03<\/strong><\/td><td>First-line metastatic TNBC, PD-1\/PD-L1 ineligible<\/td><td>Completed<\/td><td>Primary basis for EU approval<\/td><\/tr><tr><td><strong>ASCENT-04<\/strong><\/td><td>Additional first-line cohorts<\/td><td>Completed<\/td><td>Supporting data for regulatory submissions<\/td><\/tr><tr><td><strong>Supplemental US Applications<\/strong><\/td><td>Same indication<\/td><td>Under FDA review<\/td><td>Potential US approval expected Q4 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The EC approval was supported by robust clinical data demonstrating superior efficacy compared to standard chemotherapy regimens in the first-line setting for this specific patient population.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TNBC Treatment Landscape:<\/strong> Approximately 15-20% of breast cancer cases are TNBC, with limited effective treatment options particularly in the first-line metastatic setting for immunotherapy-ineligible patients<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> First-line indication could expand Trodelvy&#8217;s European addressable market by \u20ac400-500 million annually, representing a 60-70% increase over current later-line usage<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Establishes Trodelvy as the only ADC approved for first-line metastatic TNBC in Europe, ahead of competing HER2-targeted and other Trop-2 ADCs in development<\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> Strengthens Gilead&#8217;s oncology portfolio leadership while validating the Trop-2 ADC platform for additional tumor types including urothelial and lung cancers<\/li>\n\n\n\n<li><strong>Healthcare System Benefits:<\/strong> Provides an effective alternative for patients who cannot receive immunotherapy due to autoimmune conditions, organ transplant status, or other contraindications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and clinical development. Actual results may differ due to risks including competitive dynamics, pricing negotiations, reimbursement decisions, and clinical trial outcomes for additional indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,16,226,1025,18,15],"class_list":["post-68851","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-gilead-sciences","tag-nasdaq-gild","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead&#039;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy&#039;s European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68851\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead&#039;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy&#039;s European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68851\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T16:08:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-24T16:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead&#8217;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients\",\"datePublished\":\"2026-06-24T16:08:09+00:00\",\"dateModified\":\"2026-06-24T16:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Gilead Sciences\",\"NASDAQ: GILD\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68851#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68851\",\"name\":\"Gilead's Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-24T16:08:09+00:00\",\"dateModified\":\"2026-06-24T16:08:10+00:00\",\"description\":\"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy's European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68851\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68851#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead&#8217;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead's Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy's European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68851","og_locale":"en_US","og_type":"article","og_title":"Gilead's Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients","og_description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy's European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.","og_url":"https:\/\/flcube.com\/?p=68851","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-24T16:08:09+00:00","article_modified_time":"2026-06-24T16:08:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68851#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68851"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead&#8217;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients","datePublished":"2026-06-24T16:08:09+00:00","dateModified":"2026-06-24T16:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68851"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Gilead Sciences","NASDAQ: GILD","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68851#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68851","url":"https:\/\/flcube.com\/?p=68851","name":"Gilead's Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-24T16:08:09+00:00","dateModified":"2026-06-24T16:08:10+00:00","description":"Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan) as a monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. This approval significantly expands Trodelvy's European indication beyond previously approved later-line settings, addressing a critical gap in first-line treatment options for this aggressive breast cancer subtype.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68851#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68851"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68851#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead&#8217;s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC \u2013 Expanding ADC Access to Treatment-Na\u00efve Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68851"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68851\/revisions"}],"predecessor-version":[{"id":68853,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68851\/revisions\/68853"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}